Publication | Open Access

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Critical Care MedicineClinical Infectious DiseaseAnti-c5a AntibodyCovid-19 PandemicAntiviral TherapyVentilated PatientsImmunotherapyMedicineCovid-19